Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT01420549
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 129 participants
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
- Registry
-
NCT01420549
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT01420549. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-01-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
- Acronym
- LANCE
- Condition
- Hypercholesterolemia
- Condition
- Dyslipidemia
- Intervention (Drug)
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Intervention (Drug)
- Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.
Record details
- Record id
cardio:ct-nct01420549- Content hash
8605b50b57323b007d1edbb2f3827987d6be75c1641a32f2892ee5b6ad057d20